Cargando…

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolley, Elizabeth E., Zangeneh, Sahar Z., Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, Landovitz, Raphael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423859/ https://www.ncbi.nlm.nih.gov/pubmed/32052214 http://dx.doi.org/10.1007/s10461-020-02808-2

Ejemplares similares

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
por: Landovitz, Raphael J., et al.
Publicado: (2018)

Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study
por: Seneviratne, Herana Kamal, et al.
Publicado: (2021)

Correction to “Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study”
por: Seneviratne, Herana Kamal, et al.
Publicado: (2021)

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
por: Delany-Moretlwe, Sinead, et al.
Publicado: (2022)

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
por: Marzinke, Mark A., et al.
Publicado: (2023)

Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052
por: Palumbo, Philip J., et al.
Publicado: (2017)

HIV risk perception and sexual behavior among HIV-uninfected men and transgender women who have sex with men in sub-Saharan Africa: Findings from the HPTN 075 qualitative sub-study
por: Mbilizi Chimwaza, Yamikani R., et al.
Publicado: (2022)

Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083
por: Mitchell, Kate M., et al.
Publicado: (2023)

1532. Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1-Infected Subjects
por: Han, Kelong, et al.
Publicado: (2019)

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects
por: Han, Kelong, et al.
Publicado: (2022)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075
por: Sandfort, Theo G. M., et al.
Publicado: (2019)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis
por: Jamieson, Lise, et al.
Publicado: (2022)

Cabotegravir
Publicado: (2022)

1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)
por: Sinclair, Gary I, et al.
Publicado: (2023)

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305
por: Kapadia, Shashi N., et al.
Publicado: (2018)

HIV incidence in a multinational cohort of men and transgender women who have sex with men in sub-Saharan Africa: Findings from HPTN 075
por: Sandfort, Theodorus G. M., et al.
Publicado: (2021)

Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075
por: Palumbo, Philip J., et al.
Publicado: (2021)

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
por: Lou, Yu, et al.
Publicado: (2016)

1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE)
por: Czarnogorski, Maggie, et al.
Publicado: (2020)

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)
por: Rael, Christine Tagliaferri, et al.
Publicado: (2021)

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study
por: Mills, Anthony, et al.
Publicado: (2020)

The CAB software package
por: Perrin, Yves, et al.
Publicado: (1984)

A Cab Ride
por: Judson, Seth D.
Publicado: (2019)

To a Cab of the Night
por: Rosser, John E.
Publicado: (1910)

1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
por: Dandachi, Dima, et al.
Publicado: (2023)

Competencias académicas básicas (CAB)
por: Fuentes Navarro, Teresa
Publicado: (2008)

“The role of case management in HIV treatment adherence: HPTN 078”
por: Tolley, Elizabeth E., et al.
Publicado: (2022)

1024. Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study
por: Garris, Cindy, et al.
Publicado: (2023)

The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub‐Saharan Africa (HPTN 075)
por: Sandfort, Theodorus GM, et al.
Publicado: (2020)

Engaging with Community Advisory Boards (CABs) in Lusaka Zambia: perspectives from the research team and CAB members
por: Mwinga, Alwyn, et al.
Publicado: (2015)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)
por: Tolley, Elizabeth E, et al.
Publicado: (2019)

MASS DEFLECTOR APPLICATION FOR CERN’s ON-LINE ISOTOPE SEPARATOR FACILITY 077
por: Sánchez-Conejo, J
Publicado: (2004)

CabZIP23 Integrates in CabZIP63–CaWRKY40 Cascade and Turns CabZIP63 on Mounting Pepper Immunity against Ralstonia solanacearum via Physical Interaction
por: Lu, Qiaoling, et al.
Publicado: (2022)

1531. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence
por: Altamirano, Jessica A, et al.
Publicado: (2023)

AB077. Relationship of TPO-Ab and TSH with in vitro fertilization and embryo transfer
por: Wang, Liyun
Publicado: (2015)

MON-077 A Case of Growth Hormone Deficiency in Sturge-Weber Syndrome
por: Hwang, Jeongju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vko04gptphrmkp5f2tu4uj6etl